뇌졸중의 이차예방

참고문헌 (18)

1. Wiviott SD, "Prasugrel versus clopidogrel in patients with acute coronary syndromes", N Engl J Med, 357, pp.2001~2015 (2007)
2. Jernberg T, "Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease", Eur Heart J, 27, pp.1166~1173 (2006)
3. Bhatt DL, "Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial", J Am Coll Cardiol, 49, pp.1982~1988 (2007)
4. Bhatt DL, "Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events", N Engl J Med, 354, pp.1706~1717 (2006)
5. Barter PJ, "Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease", J Am Coll Cardiol, 47, pp.492~499 (2006)
6. Barter PJ, "Effects of torcetrapib in patients at high risk for coronary events", N Engl J Med, 357, pp.2109~2122 (2007)
7. LaRosa JC, "Intensive lipid lowering with atorvastatin in patients with stable coronary disease", N Engl J Med, 352, pp.1425~1435 (2005)
8. Barter P, "HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events", N Engl J Med, 357, pp.1301~1310 (2007)
9. Wang X, "Efficacy of folic acid supplementation in stroke prevention: a metaanalysis", Lancet, 369, pp.1876~1882 (2007)
10. Mant J, "Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial", Lancet, 370, pp.493~503 (2007)
11. Rothwell PM, "Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study)", Lancet, 363, pp.1925~1933 (2004)
12. Hart RG, "Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
13. Bresalier RS, "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial", N Engl J Med, 352, pp.1092~1102 (2005)
14. Kerr DJ, "Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer", N Engl J Med, 357, pp.360~369 (2007)
15. Antman EM, "Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association", Circulation, 115, pp.1634~1642 (2007)
16. Nissen SE, "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes", N Engl J Med, 356, pp.2457~2471 (2007)
17. Singh S, "Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis", JAMA, 298, pp.1189~1195 (2007)
18. Lincoff AM, "Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials", JAMA, 298, pp.1180~1188 (2007)

관련 논문AI추천